Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Donna L. Topping"'
Autor:
Emily Sherene Van Laar, Donna L. Topping, Saee Dhoble, Kinjal Parikh, Haleh Kadkhoda, Patrick Kugel, Jacob Cohen
Publikováno v:
Journal of Clinical Oncology. 39:492-492
492 Background: Immunotherapy (IO) utility in bladder cancer (UC) has expanded into multiple stages of disease. Employing IO optimally requires mastery of clinical trial data, patient eligibility criteria, and interpretation of biomarkers and determi
Publikováno v:
Cancer Research. 80:2040-2040
Background: Patients with advanced EGFR-mutated NSCLC benefit from treatment with EGFR TKIs. However, gaps in oncologists' performance hamper their ability to integrate individualized treatments into the care of patients with this disease. This study
Autor:
Smita K. Nair, P. Kelly Marcom, Kimberly L. Blackwell, Terry Hyslop, Lynn Howie, Gloria Broadwater, Sara Abbott, Donna L. Topping, Jeremy Force, Michelle Parks, Kelly Westbrook, Gretchen Kimmick, Rex C. Bentley, Sarah Sammons, Ryan O. Emerson
Publikováno v:
Clinical breast cancer. 18(5)
Background Stromal tumor-infiltrating lymphocytes (TILs) might predict pathologic complete response (pCR) in patients with HER2-positive (HER2+) breast cancer treated with trastuzumab (H). Docetaxel (T), carboplatin (C), H, and pertuzumab (P) have im
Autor:
Kimberly L. Blackwell, Lynn Howie, Rex C. Bentley, Smita K. Nair, Sara Abbott, Gloria Broadwater, Kelly E. Westbrook, Michelle Parks, Donna L. Topping, Paul K. Marcom, Jeremy Force, Gretchen Kimmick
Publikováno v:
Journal of Clinical Oncology. 34:602-602
602Background: Increased stromal tumor infiltrating lymphocytes (STILs) may predict for pathologic complete response (pCR) in HER2+ breast cancer patients treated with neoadjuvant trastuzumab (H). Taxanes (T) and carboplatin (C) have immune modulatin
Autor:
Donna L. Topping, Erika Hamilton, Gretchen Kimmick, C. Cirrincione, Jeffrey Peppercorn, Kimberly L. Blackwell, Erin Duff, P. Kelly Marcom
Publikováno v:
Journal of Clinical Oncology. 31:1076-1076
1076 Background: The FN rate for the approved regimen of TC is 5% in pivotal studies. Other small retrospective reports have reported FN rates as high as 20-35%. We report the incidence of FN from a large retrospective series of breast cancer patient